Abrocitinib Long-Term Efficacy for up to 96 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of JADE EXTEND, a Long-Term Extension Study

被引：0

作者：

Reich, Kristian ^{[1
]}

Silverberg, Jonathan I. ^{[2
]}

de Bruin-Weller, Marjolein ^{[3
]}

Deleuran, Mette ^{[4
]}

Beck, Lisa A. ^{[5
]}

Papp, Kim ^{[6
]}

Farooqui, Saleem A. ^{[7
]}

Zhang, Fan ^{[8
]}

Feeney, Claire ^{[9
]}

Koppensteiner, Herwig ^{[10
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

[3] Univ Med Ctr Utrecht, Utrecht, Netherlands

[4] Aarhus Univ Hosp, Aarhus, Denmark

[5] Univ Rochester, Med Ctr, Rochester, NY USA

[6] Papp Clin Res & Prob Med Res, Waterloo, ON, Canada

[7] Pfizer R&D UK Ltd, Sandwich, Kent, England

[8] Pfizer Inc, Groton, CT USA

[9] Pfizer Ltd, Tadworth, Surrey, England

[10] Pfizer Corp Austria GmbH, Vienna, Austria

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

44042

引用

页码：AB116 / AB116

页数：1

共 50 条

[41] Long-term efficacy of ustekinumab in moderate-to-severe psoriasis
Kimball, A. B.
Gordon, K. B.
Fakharzadeh, S.
Yeilding, N.
Szapary, P. O.
Schenkel, B.
Guzzo, C.
Li, S.
Papp, K. A.
BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (04)
[42] Long-term dupilumab treatment for 100 weeks reduces serum TARC and total IgE in patients with moderate-to-severe atopic dermatitis
Beck, L. A.
Thaci, D.
Bissonnette, R.
Deleuran, M.
Harel, S.
Chen, Z.
Shumel, B.
Rossi, A. B.
ALLERGY, 2020, 75 : 27 - 28
[43] LONG-TERM SAFETY DATA FOR DUPILUMAB UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Wollenberg, Andreas
Deleuran, Mette
Soong, Weily
Gooderham, Melinda
Bissonnette, Robert
Xiao, Jing
Khokhar, Faisal A.
Levit, Noah A.
Rodriguez Marco, Ainara
Shabbir, Arsalan
ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 35
[44] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
Wollenberg, A.
Soong, W.
Goooderham, M.
Bissonnette, R.
Xiao, J.
Khokhar, F. A.
Marco, A. R.
Levit, N. A.
Shabbir, A.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E163 - E163
[45] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
Gooderham, Melinda
Wollenberg, Andreas
Soong, Weily
Bissonnette, Robert
Xiao, Jing
Khokhar, Faisal A.
Marco, Ainara Rodriguez
Levit, Noah A.
Shabbir, Arsalan
ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 561 - 561
[46] Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab
Cioppa, Vittoria
Lazzeri, Laura
Carraro, Andrea
De Piano, Ernesto
Falcinelli, Francesca
Galluzzo, Marco
Pallotta, Sabatino
De Pita, Ornella
Russo, Filomena
DERMATITIS, 2024, 35
[47] LONG-TERM EFFICACY OF TOCILIZUMAB UP TO 3.5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN INTERIM ANALYSIS OF LONG-TERM EXTENSION STUDIES
Calvo, A.
Sid, D.
Saavedra, M.
Kissel, K.
Alecock, E.
Smolen, J.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2010, 16 (03) : S34 - S34
[48] Long-term Use of Systemic Treatments for Moderate-to-Severe Atopic Dermatitis in Adults: A Monocentric Retrospective Study
Vedie, Anne-Laure
Ezzedine, Khaled
Amazan, Emmanuelle
Boralevi, Franck
Milpied, Brigitte
Taieb, Alain
Seneschal, Julien
ACTA DERMATO-VENEREOLOGICA, 2016, 96 (06) : 802 - 806
[49] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: open-label extension study
Blauvelt, A.
Wollenberg, A.
Beck, L. A.
Chen, Z.
Vakil, J.
Khokhar, F. A.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E120 - E121
[50] Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis
Jee, Sue-Jung
Kim, Joo-Hwa
Baek, Hey-Sung
Lee, Ha-Baik
Oh, Jae-Won
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2011, 3 (02) : 89 - 95

← 1 2 3 4 5 →